Rosacea Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The rosacea market size has grown strongly in recent years. It will grow from $1.95 billion in 2024 to $2.15 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to growing awareness of rosacea, increasing access to healthcare, rising disposable incomes, government support for rosacea research and treatment,.

The rosacea market size is expected to see strong growth in the next few years. It will grow to $3.02 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to biologic therapies, demand for personalized medicine, aging population, increasing prevalence of comorbidities. Major trends in the forecast period include minimally invasive and non-invasive treatments for rosacea, digital health technologies, rosacea-specific cosmetics, non-invasive therapies.

The rising prevalence of skin diseases is expected to drive the growth of the rosacea market in the future. Skin diseases are conditions affecting the appearance, structure, and function of the skin, potentially involving the skin, hair, nails, and related tissues. Rosacea, an inflammatory skin condition, can result from various fungal infections, including Candida overgrowth. Additionally, rosacea is associated with a statistically significant increased risk of certain cancers, such as hepatic cancer, non-melanoma skin cancer, and breast cancer. For example, in February 2023, Cancer Research UK, a cancer research organization in the UK, reported that the annual number of new melanoma skin cancer cases in the UK is projected to increase from around 20,800 cases in 2023-2025 to approximately 26,500 cases in 2038-2040. This projection reflects a 9% rise in melanoma incidence rates, reaching an estimated 33 cases per 100,000 people each year by 2038-2040. Consequently, the increasing prevalence of skin diseases is contributing to the growth of the rosacea market.

The expanding use of telehealth is expected to further propel the growth of the rosacea market. Telehealth, also known as healthcare telecommunications, involves using digital technologies and communication tools to deliver healthcare services, consultations, monitoring, and education remotely. It allows patients to receive medical care, consultations, and support from healthcare providers without requiring in-person visits. The growing adoption of telehealth is a key factor in enhancing rosacea care by increasing access to care, enabling early intervention, and promoting patient education and adherence. For instance, in April 2023, the Office of the Assistant Secretary for Planning and Evaluation, a U.S.-based government department, reported that telehealth usage among adults varied between 20.5% and 24.2%, with an average of 22% during the last four weeks of 2022. Usage rates were notably lower among uninsured individuals (9.4%), young adults aged 18-24 (17.6%), and people living in the Midwest (18.7%). Therefore, the increasing adoption of telehealth is fueling the growth of the rosacea market.

The prominent companies in the rosacea market are dedicated to pioneering new products and solutions to maintain their presence in the industry. For example, in June 2022, Galderma S.A., a pharmaceutical company based in Switzerland, introduced EPSOLAY cream, a groundbreaking topical treatment. This cream is the first of its kind to utilize microencapsulated benzoyl peroxide (E-BPO), proven through scientific research to alleviate rosacea-related bumps and blemishes. EPSOLAY Cream leverages Sol-Gel Technology's proprietary patented approach, encapsulating benzoyl peroxide within silica-based microcapsules to establish a protective barrier between the medication and the skin's surface. This innovative method helps reduce the potential irritation and dryness typically associated with traditional benzoyl peroxide treatments.

In March 2022, Novan Inc., a specialty dermatology company based in the United States, completed its acquisition of EPI Health LLC for $27.5 million. This strategic acquisition is expected to empower Novan Inc. in establishing a fully integrated specialty dermatology company. It aims to bolster its presence in the specialty dermatology market and further enrich its product portfolio, particularly in the field of dermatological treatments. EPI Health LLC, a US-based pharmaceutical company, specializes in providing medications for conditions like rosacea, acne, and psoriasis.

Major companies operating in the rosacea market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Galderma S.A., Dr. Reddy's Laboratories Ltd., Lupin Limited, LEO Pharma A/S, Almirall S.A., Supernus Pharmaceuticals Inc., Taro Pharmaceuticals, Mayne Pharma, Aclaris Therapeutics Inc., Sol-Gel Technologies Ltd., Nestle Skin Health S.A., Foamix Pharmaceuticals.

North America was the largest region in the rosacea market in 2024. Asia-Pacific is expected to the fastest-growing region in the forecast period. The regions covered in rosacea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rosacea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rosacea market consists of sales of metronidazole, azelaic acid, brimonidine, oxymetazoline and tretinoin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Rosacea is a persistent skin disorder that predominantly impacts the facial area, resulting in redness, flushing, and the development of bumps, typically on the cheeks and nose. It usually emerges in adulthood and is more prevalent among individuals with fair skin. Symptoms of rosacea encompass swollen red bumps, visible blood vessels, and pustule formation.

The primary categories of rosacea include erythematotelangiectatic rosacea, papulopustular rosacea, ocular rosacea, and phymatous rosacea. Erythematotelangiectatic rosacea is characterized as a chronic inflammatory skin condition primarily affecting the face, and its treatment often involves a combination of topical medications. Various classes of drugs, including antibiotics, alpha-agonists, retinoids, corticosteroids, immunosuppressants, and others, can be administered via various routes, such as topical and oral applications. These treatments serve various end-users, including hospitals, clinics, retail pharmacies, and online pharmacies.

The rosacea market research report is one of a series of new reports that provides rosacea market statistics, including rosacea industry global market size, regional shares, competitors with a rosacea market share, detailed rosacea market segments, market trends and opportunities and any further data you may need to thrive in the rosacea industry. This rosacea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.